TTD | Drug: D01NAP

Drug General Information
Drug ID	D01NAP
Former ID	DNCL002253
Drug Name	MM-151
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Phase 1	[549340]
Company	Merrimack Pharmaceuticals
Target and Pathway
Target(s)	Receptor protein-tyrosine kinase erbB-3	Target Info	Modulator	[532567]
KEGG Pathway	ErbB signaling pathway
	Calcium signaling pathway
	Endocytosis
	Proteoglycans in cancer
	MicroRNAs in cancer
NetPath Pathway	TNFalpha Signaling Pathway
PANTHER Pathway	Cadherin signaling pathway
PANTHER Pathway	EGF receptor signaling pathway
Pathway Interaction Database	ErbB2/ErbB3 signaling events
	ErbB receptor signaling network
	a6b1 and a6b4 Integrin signaling
WikiPathways	ErbB Signaling Pathway
	Apoptosis-related network due to altered Notch3 in ovarian cancer
	Signaling Pathways in Glioblastoma
	miR-targeted genes in muscle cell - TarBase
	Heart Development
References
Ref 549340	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035447)
Ref 532567	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information